ARCUTIS BIOTHERAPEUTICS INC
NASDAQ: ARQT (Arcutis Biotherapeutics, Inc.)
Kemas kini terakhir: 15 jam lalu26.36
-0.81 (-2.98%)
| Penutupan Terdahulu | 27.17 |
| Jumlah Dagangan | 1,290,169 |
| Purata Dagangan (3B) | 2,594,581 |
| Modal Pasaran | 3,333,354,752 |
| Harga / Pendapatan (P/E TTM) | 119.82 |
| Harga / Pendapatan (P/E Ke hadapan) | 31.87 |
| Harga / Jualan (P/S) | 7.28 |
| Harga / Buku (P/B) | 14.26 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 4 Nov 2026 |
| Margin Keuntungan | 5.88% |
| Margin Operasi (TTM) | 6.91% |
| EPS Cair (TTM) | 0.220 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 45.10% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | 18.80% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 50.75% |
| Nisbah Semasa (MRQ) | 2.92 |
| Aliran Tunai Operasi (OCF TTM) | 59.96 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 32.62 M |
| Pulangan Atas Aset (ROA TTM) | 4.91% |
| Pulangan Atas Ekuiti (ROE TTM) | 14.88% |
Sentimen Berita
-
Arcutis Biotherapeutics Inc (ARQT) (Q3 2026) Earnings Call Highlights: Revenue Surges 45% to ...
07 Nov, 5:08PM
-
Arcutis Biotherapeutics Q3 Earnings Call Highlights
04 Nov, 6:14PM
-
Arcutis Announces Third Quarter 2026 Financial Results and Provides Business Update
04 Nov, 3:00PM
AISkor Stockmoo
| Nilai 30% | -3.4 |
| Harga menyiratkan pertumbuhan perolehan 37.8% setahun; perniagaan boleh membiayai kira-kira 14.9% setahun. info | |
| Hutang rendah. Keuntungan kukuh. Kecairan jangka pendek mencukupi. Aliran tunai positif. info | |
| Daripada penilaian laporan AI Insight kami tentang pulangan dijangka berbanding risiko. info | NA |
| Sejarah Penilaian info | NA |
| Pulangan atas Modal info | NA |
| Nilai Pegangan info | NA |
| Premium Risiko info | NA |
| Penilaian Pasaran info | NA |
| Masa 30% | 0.8 |
| Tiada aliran jelas sepanjang tahun lalu. Agak di bawah paras tertinggi 52 minggu. info | |
| Tiada aliran jelas: harga bergerak di sekitar purata bergeraknya. Harga hampir dengan purata itu. info | |
| Daripada analisis teknikal AI kami terhadap carta. info | NA |
| Sentimen 20% | 0.3 |
| Tiada harga sasaran terkini, jadi berdasarkan arah semakan harga sasaran. info | |
| Berita terkini kebanyakannya positif. info | |
| Sentimen Pegangan info | NA |
| Wang Pintar 20% | 3.2 |
| Institusi bersih +17.12% daripada saham dalam pemfailan 13F terkini: 196 pemegang menambah, 118 mengurang (suku berakhir 30 Sep 2026). info | |
| Kedudukan jual singkat +9.7% dari 31 Aug hingga 30 Oct 2026, 7.6 hari untuk tutup (FINRA). info | |
| Aktiviti Orang Dalam info | NA |
| Keadaan pasaran dan sektor lemah. | |
| Persekitaran pasaran berhati-hati. info | |
| Sektor ketinggalan berbanding pasaran. | |
| Tonggak-tonggak tidak sependapat, jadi skor dilemahkan. | |
| Tidak dikira dalam skor | |
| Harga tinggi berbanding pertumbuhan perolehannya. info | |
| Perolehan sesaham turun naik. Mencatat kerugian dalam tahun-tahun kebelakangan. info | |
| Corak pembalikan menaik baru-baru ini: Tukul terbalik. info | |
| Hampir dengan garis aliran jangka sederhana. info | |
| Harga hampir dengan purata 52 minggunya. Naik dalam tempoh 5 tahun. info | |
| Momentum jangka pendek menurun. info | |
| Harga hampir dengan paras sokongan. Paras sokongan dan rintangan menaik. info | |
| Skor Akhir | -0.07 |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Arcutis Biotherapeutics, Inc. | Bercampur | Menaik |
Saham Serupa
| Stok | Modal Pasaran | DY | P/E (TTM) | P/B | Skor |
|---|---|---|---|---|---|
| ARQT | 3 B | - | 119.82 | 14.26 | -0.1 |
| SYRE | 9 B | - | - | 10.08 | 1.1 |
| MDGL | 9 B | - | - | 14.74 | -0.4 |
| CORT | 7 B | - | 47.78 | 8.89 | -1.5 |
| DFTX | 5 B | - | - | 4.54 | 0.0 |
| FOLD | 5 B | - | - | - | 0.0 |
|
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 1.68% |
| % Dimiliki oleh Institusi | 122.12% |
Tiada data dalam julat masa ini.
Institusi
Pemilikan institusi: 125.70%
| Kedudukan | Pemegang | Saham |
|---|---|---|
| Bertambah | 196 | 30,954,232 |
| Berkurang | 118 | 10,907,991 |
| Baharu | 67 | 6,724,646 |
| Dijual habis | 43 | 5,202,713 |
Pemfailan SEC 13F melalui Nasdaq, pemfailan terkini hingga 30 Sep 2026. Pemfailan tiba sehingga 45 hari selepas setiap suku.
Kedudukan Jual Singkat
| Penyelesaian | Saham | Hari untuk tutup |
|---|---|---|
| 30 Oct 2026 | 18,157,145 | 7.6 |
| 15 Oct 2026 | 20,485,453 | 9.8 |
| 30 Sep 2026 | 21,688,918 | 4.8 |
| 15 Sep 2026 | 18,458,091 | 8.5 |
| 31 Aug 2026 | 16,557,048 | 9.4 |
| 14 Aug 2026 | 14,717,905 | 8.0 |
Data jual singkat FINRA melalui Nasdaq, dilaporkan dua kali sebulan.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 13 Nov 2026 | Yahoo Finance |
Arcutis Biotherapeutics (ARQT) Stock Looks Expensive Despite Its Huge Three Year Run
Arcutis Biotherapeutics has seen its share price move sharply in recent years, helped by growing attention on its dermatology franchise and new clinical milestones. With the stock now reflecting that shift, the key issue for you as an investor is whether the current valuation is still supported by… |
| 13 Nov 2026 | Yahoo Finance |
Arcutis Presents New Caregiver-Reported Outcomes Data Supporting ZORYVE® (roflumilast) Cream 0.05% for Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months at the ACAAI Annual Scientific Meeting
New INTEGUMENT-INFANT trial results demonstrate improvements in itch, reductions in symptoms, and improvements in quality of life for infants with atopic dermatitis and their familiesFindings further support investigational ZORYVE cream 0.05% to help address unmet needs in infants aged 3 to… |
| 07 Nov 2026 | Yahoo Finance |
Arcutis Biotherapeutics Inc (ARQT) (Q3 2026) Earnings Call Highlights: Revenue Surges 45% to ...
Arcutis Biotherapeutics Inc (ARQT) posted strong Q3 2026 net product revenue growth, lifted full-year guidance to $535-$545 million, and outlined multiple pipeline catalysts despite elevated expenses. |
| 06 Nov 2026 | Yahoo Finance |
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WESTLAKE VILLAGE, Calif., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the grant of an aggregate of 58,500 restricted stock units… |
| 06 Nov 2026 | Yahoo Finance |
Arcutis Biotherapeutics (ARQT) Raised 2026 Sales Guidance, Is The Upside Already Priced In?
Arcutis Biotherapeutics (ARQT) drew investor attention after reporting third quarter 2026 earnings, with net product revenue for ZORYVE up 45% year over year and full year sales guidance nudged higher. The reaction in Arcutis Biotherapeutics’ share price has been sharp, with the stock falling about… |
| 05 Nov 2026 | Yahoo Finance |
Biotech Earnings: Who Won, Who Lost And Who Pulled Off A 'Historic' Launch?
Biotech stocks offered a mixed third-quarter bag on Thursday, with Arcutis reversing and BeOne Medicines surging deeper into its buy zone. |
| 05 Nov 2026 | Yahoo Finance |
Arcutis Biotherapeutics, Inc. Q3 2026 Earnings Call Summary
Moby summary of Arcutis Biotherapeutics, Inc.'s Q3 2026 earnings call… |
| 05 Nov 2026 | Yahoo Finance |
Arcutis Begins Enrolling Phase 3 Study Evaluating ZORYVE® (roflumilast) Cream 0.3% in Moderate to Severe Atopic Dermatitis
New INTEGUMENT-3 study to evaluate efficacy, safety, and tolerability of investigational ZORYVE® cream 0.3% in individuals with moderate to severe atopic dermatitisStudy aims to expand once-daily ZORYVE cream treatment to individuals with moderate to severe atopic dermatitisBuilds on existing… |
| 04 Nov 2026 | Yahoo Finance |
Arcutis Biotherapeutics Q3 Earnings Call Highlights
Arcutis Biotherapeutics (NASDAQ:ARQT) raised its full-year 2026 net revenue guidance after third-quarter sales of its ZORYVE skin treatments rose 45% from a year earlier, driven primarily by increased patient demand. The company reported $143.9 million in third-quarter net product revenue, up 11% f… |
| 04 Nov 2026 | Yahoo Finance |
Arcutis Biotherapeutics, Inc. (ARQT) Misses Q3 Earnings Estimates
Arcutis Biotherapeutics (ARQT) delivered earnings and revenue surprises of -64.71% and +1.61%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock? |
| 04 Nov 2026 | Yahoo Finance |
Arcutis Announces Third Quarter 2026 Financial Results and Provides Business Update
Continued strong ZORYVE® (roflumilast) net product revenue growth, with Q3 revenues of $143.9 million, +45% versus Q3 of 2025, and +11% versus Q2 of 2026, driven by strong demand growthRaised 2026 full-year net product sales guidance to $535 million–$545 millionPartnered with World Champion gymnast… |
| 29 Oct 2026 | Yahoo Finance |
Sarepta Therapeutics (SRPT) Earnings Expected to Grow: Should You Buy?
Sarepta Therapeutics (SRPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
| 28 Oct 2026 | Yahoo Finance |
Arcutis Biotherapeutics, Inc. (ARQT) Reports Next Week: Wall Street Expects Earnings Growth
Arcutis Biotherapeutics (ARQT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
| 28 Oct 2026 | Yahoo Finance |
Arcutis Appoints Rob Scott, MD to Board of Directors
WESTLAKE VILLAGE, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovation in immuno-dermatology, today announced that Rob Scott, MD has been appointed to the Arcutis Board of… |
| 27 Oct 2026 | Yahoo Finance |
Arcutis Management to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference
WESTLAKE VILLAGE, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis management will present at the Guggenheim 3rd… |
| 21 Oct 2026 | Yahoo Finance |
Arcutis to Report Third Quarter 2026 Financial Results and Host Conference Call on November 4, 2026
WESTLAKE VILLAGE, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will report its third quarter 2026 financial results and… |
| 19 Oct 2026 | Yahoo Finance |
Arcutis Biotherapeutics (ARQT) Gets New Rating Uprgades from 2 Analysts; Shares Climb
Arcutis Biotherapeutics (NASDAQ:ARQT) saw its share price jump by 10.65 percent to close at $31.89 apiece after earning a bullish outlook and a double-digit price target hike from an analyst. In its market note, investment firm Guggenheim upgraded its stock target by 15.8 percent to $44 from $38… |
| 19 Oct 2026 | Yahoo Finance |
Clinical Data Update Could Shape The Case For Arcutis Biotherapeutics Stock
Arcutis Biotherapeutics reported past conference data on its ZORYVE portfolio, including Phase 2 INTEGUMENT-INFANT results in atopic dermatitis and multiple analyses across creams and foams for plaque psoriasis and seborrheic dermatitis, covering different strengths, formulations, and approved age… |
| 19 Oct 2026 | Yahoo Finance |
Arcutis Soars 12% as Guggenheim Lifts Target to $44 on “Growing Conviction” in 2027
Key TakeawaysArcutis shares rose 12% after Guggenheim raised its price target to $44 from $38 and kept its Buy rating, citing “growing conviction” about 2027. It’s the second bullish call in a week, after Cantor Fitzgerald started coverage on Thursday with an Overweight rating and a $48 target. |
| 12 Oct 2026 | Yahoo Finance |
2 Stocks That Could Soar in Q4
These growth companies offer investors the potential for near-term upside from fourth-quarter catalysts and long-term growth from realizing value in their pipelines. |
| Papar semua | ||
Isyarat Terkini corak lilin dan silang EMA
Persediaan Teknikal Sederhana
AI Analisis Teknikal
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |